Kornimate/medical-research-clean huggingface dataset:
efficacy of percutaneous spg block in aneurysmal sah

Conditions: Subarachnoid Hemorrhage; Headache

Summary: researchers are trying to develop alternative means to help patients with headache pain secondary to aneurysmal subarachnoid hemorrhage (bleeding about the brain).

this study is an open label, feasibility study that will consist of fifteen patients. this study will enroll only patients who have aneurysmal sah that are secured by endovascular coiling. when a patient notes a severe headache which requires medical intervention on at least day 3 of the hospital admission, they will be asked if they would like to participate in an open label trial to use a bilateral sspgb in addition to traditional medical management per unit protocol. the risks and benefits of the procedure will be explained to the patient. the patient will then either agree or disagree. if the patient disagrees, they will not be enrolled in the study. if the patient agrees, they will sign an informed consent and will be enrolled. inclusion and exclusion criteria will be reviewed before enrolling a patient. the patients will first rate their pain from 0-10 on the numeric rating scale (nrs) (10 being the most severe). if their pain is at a level 5 or more and it is not responsive to traditional medical therapies, they will be a candidate for the study. the patients will receive bilateral injections as outlined below (5 ml: 4.5ml of 0.5% bupivacaine and 0.5ml of 10mg/ml dexamethasone on each side for total volume of 10 ml). thirty minutes later and 24 hours following injection, the patient will rate their pain from 0-10 on the nrs. the description of the procedure is stated below. a success would be considered a drop in their pain score of at least 2. adverse effects will also be recorded 30 minutes after the procedure and the following day. chart review on both provider and nursing notes will be performed on subsequent days to evaluate for adverse effects.

Eligibility criteria:
inclusion criteria: * age 18 and older * aneurysmal sah in anterior/middle cerebral compartment * aneurysm must be secured endovascular with coiling * the patient or patient's surrogate should be able to give informed consent and understand the risks of this study * pain nrs ≥ 5/10 in severity exclusion criteria: * non aneurysmal, traumatic sah * posterior fossa aneurysm ruptures * pregnancy * transcranial doppler velocities suggestive of or approaching vasospasm

Keywords: sphenopalatine ganglion block
sleep disorders and the onset and progression of als

Conditions: Amyotrophic Lateral Sclerosis

Summary: 200 cases of als patients were collected to explore whether sleep disorders are related to earlier onset age, and whether sleep disorders accelerate the progress of als and shorten the survival time of als patients.

200 patients with als were collected. 1) sleep disorders were assessed by pittsburgh sleep quality index (psqi) and epworth sleepiness scale (epworth) at baseline sleeping scale，ess）； 2) name, age, gender and onset site were collected to explore whether sleep disorders were associated with earlier onset age; 3) the patients' function (alsfrs-r) at baseline and every 3 months within 2 years were collected, and the end-point time (death and invasive breathing) was recorded to evaluate whether sleep disturbance accelerated the decline of patients' function and shortened their short-term survival.

Eligibility criteria:
inclusion criteria: * patients who have been diagnosed in the department of neurology of the third hospital of beijing medical university since august 2020. the clinical diagnosis of patients with amyotrophic lateral sclerosis includes: probable and define; * informed consent has been signed. exclusion criteria: * those who can not cooperate to complete the scale and receive follow-up.
a comparison of specialized versus standard compression after saphenous ablation

Conditions: Varicose Veins

Summary: the purpose of this study is to determine if the use of specialized compression garments, in comparison to standard compression, improves early patient outcomes after endovenous ablation.


Eligibility criteria:
inclusion criteria: * age 18 years and above * ceap class c2 or c3 disease * incompetence of the great saphenous vein defined a reflux persisting\>0.5 seconds in the upright position * planned endovenous ablation of the great saphenous vein exclusion criteria: * inability of patient or legal guardian to provide informed consent * previous history of dvt * clinical evidence of significant chronic venous disease (ceap classes c4, c5, c6) * planned concomitant phlebectomy or sclerotherapy within 4 weeks of endovenous ablation * documented allergy or intolerance to compression stockings * arterial insufficiency as documented by an ankle-brachial index \<0.5 * known prothrombotic condition * life expectancy less than 1 year * inability to return for follow-up due to geographic inaccessibility, concurrent medical conditions or substance abuse * weight greater than 220 pounds or height \> 6'4"
remote video consultation for quality of life assessment in patients hospitalised after covid-19 infection

Conditions: Covid19

Summary: around 90.000 patients have been hospitalised due to covid-19 infection in france between march 1st and june 15th; 19% of those requiring intensive care. approximately 80% of these patients have been discharged home by september 30th. nonetheless, covid-19 infection along with intensive care consequences are very likely to impede those patients quality of life and functional capacities. this study aims to describe the quality of life outcomes and functional capacities of covid-19 survivors, at least 6 months after primary care hospital discharge.


Eligibility criteria:
inclusion criteria: * adult patient * covid-19 hospitalisation at le havre hospital between march 1st and may 11th * non-opposition during first phone contact exclusion criteria: * guardianship * juvenile patients * pregnancy * inability to communicate * cognitive disorders * deceased patient
clinical study in treatment of malignant ascites of ovarian cancer with intraperitoneal injection bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy

Conditions: Ovarian Cancer With Malignant Ascites

Summary: to study the efficacy and safety of intraperitoneal injection bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy in treatment of malignant ascites of ovarian cancer. to analyze the clinical significance of the concentration change of vascular endothelial growth factor (vegf) in ascites in treatment of intraperitoneal injection bevacizumab


Eligibility criteria:
inclusion criteria: * signed informed consent obtained prior to initiation of any study-specific procedures and treatment as confirmation of the patient's awareness and willingness to comply with the study requirements. * histologically confirmed and documented ovarian cancer with malignant ascites. * ecog(eastern cooperative oncology group, ecog) ps 0-2. * life expectancy of \>3 months. * no serious inadequate bone marrow function, liver and renal function or significant cardiovascular disease. exclusion criteria: * known hypersensitivity to any of the study drugs or excipients. * any current anti-cancer therapy. * no evidence of ascites. * key organ dysfunction. * significant cardiovascular disease (e.g. congestive heart failure (chf), uncontrolled cardiac arrhythmia, angina, heart valve disease, myocardial infarction and refractory hypertension need to be long time controlled by medicine). * non-healing wound, ulcer or bone fracture. * uncontrolled psychiatric history.
o-arm assessment of vertebral movement using st2r technique

Conditions: Scoliosis; Adolescence

Summary: the study is quantifying how the patients' back has been corrected using medicrea's hardware through imaging taken before,during and after the surgery.

visits include the pre-operative visit, 1 and 2 year follow-up visits. participation includes answering questions and filling out questionnaires. there are no immediate benefits by joining this study, but could potentially help define better techniques for the future spine surgeries. the risks involved in this study are minimal and there are no alternatives to this study.

Eligibility criteria:
inclusion criteria: * adolescent idiopathic scoliosis requiring selective thoracic posterior spinal instrumentation and fusion with the pass lp system (screws, rods, hooks) and unid rod technology * age between 10 and 21 * lenke type 1 curve * consent and assent to participate in the study exclusion criteria: * age superior to 21 years * spinal deformities other than lenke 1 type * use of implant other than those from the pass lp system or sublaminar bands * neuromuscular or degenerative scoliosis * spinal cord abnormalities with any neurologic symptoms or signs * spinal cord lesions requiring neurosurgical interventions, such as hydromyelia requiring arnold chiari decompression * primary muscle diseases (e.g. charcot-marie tooth, guillain-barre syndrome, cerebral palsy, or spina bidifa, neurofibroma) * primary abnormalities of bones (e.g. osteogenesis imperfect) * congenital scoliosis * scoliosis requiring anterior release * previous spinal surgery * absence of required preoperative data (diagnosis, consent...)
provider burnout during covid-19

Conditions: Perceived Organizational Support, Anxiety, Burnout

Summary: since the novel coronavirus, sars-cov-2, was first reported in the hubei province of china in december 2019, the us has become an epicenter for the pandemic, accounting for more than 220,000 cases and 4,800 deaths (cdc). the rapid spread of the associated disease, covid-19, has overwhelmed healthcare systems in spite of unprecedented measures to reduce contagion. the resulting uncertainty with regard to the duration and magnitude of the pandemic and limited availability of resources and treatment have been detrimental to the mental health of frontline healthcare providers (nih). preserving the psychological wellbeing of these individuals is paramount to mitigating the effect of covid-19 and delivering optimal patient care. of particularly grave concern is how professional and personal distress caused by the covid-19 pandemic will affect provider burnout (lai et al. jama network open 2020). professional burnout, characterized by emotional exhaustion, career de-prioritization, and loss of self-efficacy, represents a significant threat to the us healthcare system (shanafelt et al. ann surg 2010; han et al. annals of internal medicine 2019). while burnout has been described as a reaction to chronic work-related stress (melamed et al. psychol. bull. 2006), individual factors such as anxiety increase susceptibility to burnout (sun et al. j occup health 2012). although data suggests that occupational stress might amplify risk of anxiety (digiacomo and adamson j allied health 2001), we have yet to understand how intensified anxiety among frontline providers during global health crises contributes to burnout. similarly, it is unknown whether factors such as perceived organizational support (pos), a key driver of job satisfaction and performance (muse and stamper, j managerial issues 2007), modify anxiety and burnout under these circumstances. we hypothesize that diminished pos in response to the covid-19 pandemic is associated with burnout and that this relationship is mediated by an increase in providers' anxiety. delineating this relationship is a critical first step in developing interventions that ease the mental health burden of this pandemic and future crises for healthcare providers.


Eligibility criteria:
inclusion criteria: * all upmc healthcare providers with patient-care responsibilities (respiratory therapists, physical therapists, nursing staff, residents, attendings, midlevel providers, and clinical faculty) will be contacted via email and asked if they would be willing to participate in this study (participant recruitment email). exclusion criteria: * all individuals \<18 yo and those providers without direct patient-care responsibilities will be excluded.
study of zinc for wilson disease

Conditions: Wilson Disease

Summary: objectives: i. establish the safety and efficacy of extended maintenance zinc therapy in 200 patients with wilson disease. ii. establish further the role of zinc in the prophylactic treatment of presymptomatic patients by increasing the current cohort from 80 to at least 100 patients. iii. establish further the role of zinc therapy in pregnant patients with wilson disease. iv. establish further the role of zinc therapy in children with wilson disease.

protocol outline: patients receive copper regulation therapy with zinc acetate: an existing cohort on maintenance therapy will be followed for long-term data collection; presymptomatic patients are treated prophylactically; and pregnant patients are evaluated for fetal outcome. all patients are evaluated for copper balance, clinical control, and toxicity.

Eligibility criteria:
protocol entry criteria: wilson disease presymptomatic, pregnant, and children 16 years or younger patients eligible patient age: any age, including children

Keywords: wilson disease inborn errors of metabolism rare disease
hypoalgesic effect of cervical manipulation

Conditions: Pain

Summary: this study evaluates the hypoalgesic effect of global and specific cervical joint manipulation in healthy individuals. at first the participants received one of the interventions and after 48 hours, the other.

cervical joint manipulation (cjm) are often used for pain treatment. joint manipulation generates a series of stimuli within the central nervous system through the activation of proprioceptors located in the joint capsule or muscles, stimulates the pag, causing pain inhibition by activation of non-opioid descending inhibitory pathways.

Eligibility criteria:
inclusion criteria: * healthy subjects of both sexes * without pain complaints in the last 90 days exclusion criteria: * previous spinal surgeries * spinal canal stenosis * vertebral fracture * spondylolisthesis * cancer * acute infections * hemorrhagic disorders * active tuberculosis * deep vein thrombosis * osteoporosis * rheumatic diseases * metabolic diseases * cardiorespiratory diseases * smoking injury * musculoskeletal injury * use of pacemaker * women in menstrual period * pregnant women * use of pain-killers in the last 48 hours * use of anti-inflammatory drugs in the last 48 hours * previous joint manipulation treatments * aversion to cervical joint manipulation * positivity in the vertebral artery test * headache in the last seven days

Keywords: joint manipulation cervical pressure pain manual therapy
correlation between serum anti-müllerian hormone & müllerian ducts anomalies in infertility

Conditions: Infertility

Summary: anti-müllerian hormone (amh), also known as müllerian inhibiting substance, is a dimeric glycoprotein that belongs to the transforming growth factor-beta family. it is involved in the regression of the müllerian ducts during male fetal development. in the female, amh is solely produced by the granulosa cells of preantral and small antral follicles, and regulates ovarian activity and follicular steroidogenesis

following approval of the internal review board of egyptian ivf-et center, a retrospective analysis will be undertaken where a detailed review of the patients files who underwent intracytoplasmic sperm injection (icsi) trials starting january 2010 till january 2015 will be done. patients with diagnosed mullerian anomalies will have their name , age ,duration of infertility, serum fsh, lh ,\& amh levels recorded. the method of diagnosis (hsg, 3d/ultrasonography, hysteroscopy, or laparoscopy) will also be documented.

Eligibility criteria:
inclusion criteria: * women with diagnosed mullerian anomlies whether clinically or through imaging exclusion criteria: * previous ovarian surgery * ovarian drilling * polycystic ovarian syndrome (pcos).

Keywords: anti-müllerian hormone (amh) mullerian anomalies icsi
rise semi compliant balloon study in patient with cad

Conditions: Coronary Artery Disease

Summary: single arm, prospective, multi-center, trial designed to enrol approximately 66 patients. all patients will undergo pci using at least one rise sc balloon as per routine clinical practice and will be followed until discharge for data collection. patients will be enrolled in up to 5 investigational sites in switzerland. the patients will be followed up until discharge or until 7 days, whichever comes first.


Eligibility criteria:
inclusion criteria: * general inclusion criteria 1. subject must be at least 18 years of age. 2. subject or a legally authorised representative must provide written informed consent prior to any study related procedure. 3. subject must have stenotic lesion(s) in native coronary arteries or bypass grafts that are suitable for percutaneous coronary intervention. 4. subject must agree to undergo all protocol-required follow-up procedures. 5. subject must agree not to participate in any other clinical study during hospitalisation for the index procedure. * angiographic inclusion criteria all angiographic inclusion criteria are based on visual estimation. 1. de novo or restenotic lesions in native coronary arteries or bypass grafts. 2. a maximum of two lesions, with either both in one vessel or one lesion in each of two vessels. 3. the target lesion(s) must have a diameter stenosis of ≥ 50% by visual estimation or online quantitative coronary angiography (qca) and may include chronic total occlusions (cto). exclusion criteria: * general exclusion criteria 1. planned use of a non-study angioplasty balloon during the procedure for pre-dilatation or dilatation of the lesion. 2. subject has a known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, other anti-platelet medications, or sensitivity to contrast media, which cannot be adequately pre-treated. 3. subject has a platelet count \ 700,000 cells/mm3. 4. subject is currently participating in an investigational study that may confound the treatment or outcomes of this study. 5. subject is pregnant or nursing. female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test. * angiographic exclusion criteria all angiographic exclusion criteria are based on visual estimation. 1. unprotected left main coronary artery disease 2. more than two lesions requiring treatment. tandem lesions, defined as multiple, focal lesions that can be covered by one balloon, will be considered as a single lesion. 3. coronary artery spasm in the absence of significant stenosis. 4. anticipated need for plaque modification using rotational/orbital atherectomy or intravascular lithotripsy. note: the use of scoring or cutting balloons after (pre)-dilatation with the study device is allowed. 5. additional clinically significant lesion(s) in any coronary arteries or bypass grafts for which pci may be required during hospitalization for the index procedure (in-hospital staged pci).
thin prep versus traditional cytological procedure for lung cancer

Conditions: Lung Cancer

Summary: in the diagnosis of lung cancer, the cytological sample obtained during bronchoscopy (fbs), has an increasingly important role in the characterization of malignancy. the cytological sample can be harvested during bronchoscopy by bronchial brushing, bronchial lavages or fine needle aspiration. immunocytochemical staining allows not only to discriminate between small cell lung cancer versus non-small cell lung cancer (nsclc), but also to identify the expression of specific markers such as ttf-1, ck7, ck20, 4a4, 34βe12 and p63. thin prep is a technique for cytological assay already validated and largely used in the immunocytochemical determination of gynaecologic specimens. further studies are required to asses the accuracy of this technique compared to conventional smear in cytological airway samples obtained by fine needle aspiration.

patients undergoing fbs for lung cancer diagnosis purpose will be enrolled in the study. during fbs fine need aspiration (fna) will be performed. four samplings by fna will be performed in each patient. two samplings will be processed with thin prep technique and two samplings with the traditional procedure. to avoid sampling procedures-related bias, the first harvested sample will be randomly tested with thin prep or traditional technique.

Eligibility criteria:
inclusion criteria: * fbs undergoing bronchoscopy for diagnostic purpose of lung cancer. * informed consent. * asa classification 1-3. exclusion criteria: * patients intubated. * patients with respiratory failure.

Keywords: lung cancer bronchoscopy fine need aspiration cytochemical assays
survivor mhealth: wearable devices in cancer survivors

Conditions: Cancer; Cardiovascular Diseases

Summary: the survivor mobile health (mhealth) study is testing the use of wearable devices (fitbits) and a smartphone application in cancer survivors. the goal of the program is to increase survivor's physical activity levels. the fitbit will be synced to the app and participants will receive messages and notifications about their activity levels. participants will also complete surveys through the app asking how useful it is and ways to improve it. the study team will conduct qualitative interviews at the completion of the 3 months to see how participants liked the program, and ways it can be improved and make it more specific to cancer survivors. the study team will also conduct interviews with providers and clinic staff to assess their perceptions of patient digital health programs and preferences for receiving patient-generated health data.


Eligibility criteria:
aims 1 and 2 inclusion criteria: 1. past cancer diagnosis 2. at least 18 years of age 3. capacity to provide informed consent 4. medically cleared to perform physical activity (as noted by physical activity readiness questionnaire form or physician's clearance if needed) 5. owns a smartphone aims 1 and 2 exclusion criteria: 1. is a prisoner 2. non-english speaking 3. is unable to provide consent 4. under 18 years of age 5. no prior cancer diagnosis 6. does not own a smartphone aim 3 inclusion criteria: 1. are a current umass memorial cancer clinic patient navigator, oncologist, radiologist, or cardiologist 2. consent to participate aim 3 exclusion criteria: 1. not currently employed at umass memorial 2. not involved in direct treatment of care coordination of cancer patients

Keywords: physical activity wearable communication